Skip to content
Study details
Enrolling now

Dose Escalation and Dose Expansion Study of MDX2001

ModeX Therapeutics, An OPKO Health Company
NCT IDNCT06239194ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

115

Study length

about 4.7 years

Ages

18+

Locations

6 sites in CO, FL, MA +2

What this study is about

This trial is testing a treatment called MDX2001 in people with advanced solid tumors. The goal is to see if the treatment is safe, well-tolerated, and helps fight cancer cells. It includes different phases to determine the best dose for further development.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take MDX2001

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: All Phases: Adverse events (AEs), Phase 1b and Phase 2a: Objective response rate of MDX2001

Secondary: All Phases: Disease control rate (DCR), All Phases: Duration of response (DOR), All Phases: Pharmacokinetic Parameter Cmax of MDX2001, All Phases: Pharmacokinetic parameter area under the curve (AUC(0-T)) of MDX2001, All Phases: Progression free survival (PFS), Phase 1a: Objective response rate of MDX2001

Body systems

Oncology